Macular Degeneration Information
Nanosecond Laser Treatment for Dry Macular Degeneration
A new nanosecond laser treatment for dry macular degeneration is being tested at the Australian Centre for Eye Research. It is hoped this new treatment will slow or reverse the effects of dry macular degeneration, one of the most common causes of vision loss in the aging population. In a previous trial of 50 patients, it was shown that this new technique may be effective at slowing the eye … [Read More...]
Lucentis Treatment coming to Cape Breton, Nova Scotia
People diagnosed with wet macular degeneration in the Cape Breton, Nova Scotia area will now have access to lucentis as a treatment option. Premier Darrell Dexter made the announcement indicating that that both Lucentis and Avastin treatments will be made available for people who have Pharmacare in the province. Wet Macular Degeneration is the most severe form of the eye disease that attacks … [Read More...]
Stem Cells Implanted into Patient with Dry Macular Degeneration
Stem cells have become the corner stone of research into providing revolutionary treatments for dry macular degeneration. Continuing its Phase I & Phase II clinical trials, StemCells Inc has transplanted stem cells into its first patient suffering from dry macular degeneration. Macular degeneration is an eye disease more common among people aged 50 and older. According to the National … [Read More...]
Eylea Approved for Macular Degeneration Treatment
The FDA has granted approval to the age-related macular degeneration treatment Eylea, clearing the way to provide another form of treatment for the leading eye disease causing blindness in the elderly. Similar to other macular degeneration drugs, Eylea inhibits the growth of abnormal blood vessels in the retina. These abnormal blood vessels are charactestic for the most severe and fastest … [Read More...]
Genetic Mutation Identifies High Risk of Macular Degeneration
A rare genetic mutation has been identified that predicts a high risk of macular degeneration. Macular degeneration is seen as the leading cause of blindness in the elderly. Having a genetic mutation discovered that may predict the risk of the eye disease will provide insight into developing new treatments and in prevention. Previous research had identified genetic variants that predict … [Read More...]
Possible Lucentis Side-Effects Discovered
Researchers may have uncovered a side-effect in the macular degeneration treatment Lucentis. Lucentis is the leading treatment for wet macular degeneration. However, researchers at the Mayo Clinic have discovered this drug may cause increased pressure inside the eyes of some patients who have received the drug to treat their eye disease. Dr. Sophie Bakri began noticing patients in her … [Read More...]
Macular Degeneration Drugs
With age-related macular degeneration recognized as the leading cause of blindness in the aging population, developing drugs to combat the eye disease has become a priority for many pharmaceutical companies. While there is no cure for macular degeneration, there are several drugs on the market used to treat the most severe form of the eye disease, wet macular degeneration. There is no drug to … [Read More...]
Daily Aspirin Increases Risk of Macular Degeneration
New research has shown seniors taking a daily dose of aspirin are twice as likely to develop late stage macular degeneration than people who don't take the drug. While aspirin does not directly cause macular degeneration, researchers are concerned that aspirin may increase the severity of the eye disease. When you consider the number of seniors who take a daily dose of aspirin to lower their … [Read More...]
Gene Therapy and Stem Cell Therapy for Macular Degeneration
Macular Degeneration has been identified as a leading cause of blindness and vision loss among older people. Because of better diagnostic techniques in recent years, more and more people are being diagnosed with this eye disease. Research has turned to both gene therapy and stem cell therapy as potential treatments for macular degeneration. It has shown promise in several recent clinical … [Read More...]
Avastin Injections Reported to Cause Blindness
Health authorities in Florida and Tennessee have indicated several people suffering from wet macular degeneration recently treated with the Avastin have been blinded. Approved initially as a cancer drug, Avastin has been used to treat macular degeneration as an off-label treatment because it costs approximately $50 per treatment compared to $2,000 for Lucentis. Macular degeneration is the … [Read More...]
Recent Comments